Cerivastatin approval expands HMG-CoA reductase inhibitor choices.
D017277:Drug Approval; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D006937:Hypercholesterolemia / Q000188:drug therapy; D011725:Pyridines / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D004791:Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011725:Pyridines; C086276:cerivastatin